Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bladder Instillations Clear all
Recruiting Not applicable Interventional

Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life

NCT06163469
View directory record Official record
Conditions
Neurogenic Bladder, Urinary Retention
Interventions
Bladder instillation with Irrisept
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Not listed Phase 3 Interventional

Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

NCT00003725
View directory record Official record
Conditions
Bladder Cancer
Interventions
valrubicin, conventional surgery
Drug · Procedure
Lead sponsor
Anthra Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722
View directory record Official record
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Interventions
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Drug
Lead sponsor
enGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)

NCT01731470
View directory record Official record
Conditions
Interstitial Cystitis, Pelvic Pain
Interventions
Liposomes
Biological
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 24, 2026, 5:36 AM EDT
Withdrawn Phase 2 Interventional

A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia

NCT01048177
View directory record Official record
Conditions
Vulvodynia
Interventions
Bladder instillation with heparin/ lidocaine
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 3 Interventional

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

NCT04865939
View directory record Official record
Conditions
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Interventions
sterile water irrigation, Gemcitabine
Procedure · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic Characteristics (ICEPAC) Study

NCT01616992
View directory record Official record
Conditions
Interstitial Cystitis/Painful Bladder Syndrome, Myofascial Pelvic Pain
Interventions
Bupivacaine
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
2
States / cities
Akron, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

NCT05737121
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
VNX001, Placebo, Lidocaine, Heparin
Drug
Lead sponsor
Vaneltix Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Escondido, California • Los Angeles, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Early Phase 1 Interventional

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

NCT04369560
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM)
Diagnostic Test · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Terminated Not applicable Interventional Results available

Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection

NCT02202044
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Intravesical BCG and EMDA/MMC
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PK and Safety of SI-722 in IC/BPS

NCT04208087
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
SI-722, Placebo
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Los Angeles, California • Murrieta, California • The Villages, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
PF-08052667, Sasanlimab, BCG, PF-02921367
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
54
States / cities
Birmingham, Alabama • Ruskin, Florida • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT06929286
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer
Interventions
Nadofaragene Firadenovec, Gemcitabine, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

NCT03658304
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Mitomycin c
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 24, 2026, 5:36 AM EDT
Completed No phase listed Observational

Evaluation of a Patient-Reported Symptom Index for NMIBC

NCT03091764
View directory record Official record
Conditions
Superficial Bladder Cancer
Interventions
Not listed
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Kansas City, Kansas • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

NCT00583349
View directory record Official record
Conditions
Bladder Cancer
Interventions
Abraxane
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Recruiting Phase 3 Interventional

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374
View directory record Official record
Conditions
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Interventions
Nadofaragene Firadenovec
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
52
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer

NCT03854721
View directory record Official record
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
VAX014
Drug
Lead sponsor
Vaxiion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Denver, Colorado • Iowa City, Iowa • Edison, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 24, 2026, 5:36 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

NCT03022825
View directory record Official record
Conditions
Bladder Cancer
Interventions
N-803 and BCG, N-803
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
28
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing Two Bladder Instillations for IC/BPS

NCT03463915
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Bladder instillation WITH triamcinolone acetonide, Bladder instillation WITHOUT triamcinolone acetonide
Drug
Lead sponsor
Olivia Cardenas-Trowers, M.D.
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 24, 2026, 5:36 AM EDT
Not listed Phase 2 Interventional

Heparin Intraoperative Instillation for Lower Urinary Tract Symptoms After Benign Hysterectomy

NCT03633994
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Postoperative Urinary Tract Infection
Interventions
Heparin, Normal saline
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

NCT05085977
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
TARA-002
Biological
Lead sponsor
Protara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 24, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

Paclitaxel in Treating Patients With Early-Stage Bladder Cancer

NCT00002917
View directory record Official record
Conditions
Bladder Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 24, 2026, 5:36 AM EDT
Not yet recruiting Phase 4 Interventional

A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections

NCT07387315
View directory record Official record
Conditions
Overactive Bladder, Neurogenic Bladder, Urge Incontinence, Pain, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Bladder Neurogenesis, Urinary Incontinence, Urge, Pelvic Floor Disorders
Interventions
Pro-Nox Nitrous Oxide/Oxygen Delivery System, Standard Care for Bladder Botox Injection, Sham Mask
Drug · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 24, 2026, 5:36 AM EDT